Public health partnership Aegis Sciences Corporation has recently been selected by the CDC as a commercial laboratory to participate in a pioneering public health data accessibility initiative, signaling strong potential for government and large-scale public health collaborations that can be leveraged for grant-supported testing programs and compliance services.

Adherence and safety tools The launch of MedProtectCDM positions Aegis as a provider of medication adherence and drug-drug interaction insights, offering a scalable selling point to healthcare systems, payers, and integrated delivery networks seeking to improve clinical decision support and reduce adverse events.

NPS leadership Aegis has led industry NPS testing since 2020 with bi-annual menu updates aligned with CFSRE and SOFT recommendations, presenting an opportunity to upsell updated toxicology panels to hospitals and specialty clinics seeking state-of-the-art substance use and drug monitoring capabilities.

Integrated testing ecosystem Beyond toxicology, Aegis offers molecular diagnostics, clinical trial support, sports anti-doping, and forensic testing, enabling cross-sell to hospitals, athletic programs, and research organizations looking for a single vendor to cover diverse laboratory testing needs.

Strategic partnerships Ongoing collaborations with EHRs and industry players (PIMSY EHR, Quadax revenue cycle management, McNabb Center research) indicate a strong channel for partner-led deals and co-marketing opportunities to expand penetration in specialty care settings and behavioral health networks.